Blog
New
From Wet Lab to In-Silico
From Wet Lab to In-Silico
Barkha Pradhan
5 Min Read
Share
From Wet Lab to In-Silico: How Computational Assay Design Enables Scalable Diagnostics
Designing a diagnostic test once started in the lab, but today it increasingly starts on a computer. As diagnostics move toward larger screening programs, faster turnaround times, and lower costs, traditional trial-and-error assay development is no longer enough. This is where computational (in-silico) assay design comes in.
In this blog, we'll walk through what computational assay design actually means, how assays are designed today, where current approaches slow down or break at scale, and how in-silico design helps diagnostics scale efficiently.
What Is Computational Assay Design?
At its core, computational assay design means using algorithms, biological data, and simulations to design and evaluate diagnostic assays before they reach the wet lab.
Instead of testing every primer, probe, or target experimentally, designs are screened digitally, performance is predicted using real genomic data, and weak designs are eliminated early. This approach doesn't replace the lab; it reduces unnecessary lab iterations and helps teams arrive at better assays faster.
How Diagnostic Assays Are Traditionally Designed
Identifying Target Genes or Regions
Most diagnostic assays, whether for infectious diseases, inherited conditions, or cancer, follow a similar path: identify target genes or regions, design primers or probes, test them experimentally, redesign if performance is poor, and repeat until the assay works.
Challenges with Traditional Approaches
While this approach works for small studies, it becomes problematic when panels include dozens or hundreds of targets, samples come from genetically diverse populations, or assays need to scale across multiple labs or sites. Each redesign cycle costs time, reagents, and effort.
Where Traditional Assay Design Struggles at Scale
Too Many Targets, Too Little Time
Modern diagnostics often require highly multiplexed panels, high coverage, and minimal cross-reactivity. Manually evaluating every design combination quickly becomes impractical.
Population Bias
An assay that works well in one population may perform poorly in another due to genetic variation, mutations at primer-binding sites, or emerging strains (especially in infectious diseases).
Late Discovery of Design Issues
Problems like poor specificity, dropouts, or unexpected cross-reactivity are often discovered only after wet-lab testing, when changes are expensive.
Difficulty Standardising at Scale
When assays move from development to deployment, minor design differences can impact reproducibility and scaling across labs becomes harder.
How Computational Assay Design Changes the Workflow
Computational design shifts key decisions earlier in the process. In-silico design allows teams to evaluate thousands of candidate designs virtually, test designs against real genomic databases, simulate edge cases before lab validation, and narrow down to the most robust candidates. This results in fewer wet-lab iterations, better-performing assays, and faster time to deployment.
What This Looks Like in Practice
Target Selection Using Curated Genomic Data
Primer/Probe Design with Specificity Checks
In-silico Validation Against Known Variants
Cross-reactivity and Coverage Assessment
Design Optimisation Before Lab Testing
By the time the assay reaches the bench, it is already pre-filtered for performance.
Why This Matters for Scalable Diagnostics
As diagnostics move toward population-scale screening, surveillance programs, and rapid outbreak response, the cost of inefficient design multiplies. Computational assay design helps ensure that assays are robust across populations, faster to develop, easier to standardise, and more cost-effective at scale. This is especially critical for programs where delays or failures directly impact public health outcomes.
Where AlgoBio Fits In
Sequence Transduction for Scalable Assay Design
AlgoBio addresses this challenge through its proprietary Sequence Transduction platform, a molecular computing based approach that rethinks how nucleic acid assays are designed and scaled. Instead of tying detection directly to target-specific primers, Sequence Transduction converts diverse DNA or RNA targets into programmable proxy sequences that can be quantified using standard qPCR or digital PCR workflows.
Universal Readout Architectures
This decoupling of target recognition from signal readout allows teams to reuse the same PCR chemistry even as targets change, combining programmable sequence transducers, universal readout architectures compatible with existing qPCR and dPCR infrastructure, and molecular logic and multiplexing strategies that enable multiple targets to be processed within a single tube.
Algorithmic Decoding via Tapestry
The platform uses algorithmic decoding via the Tapestry platform, translating proxy signals back into biologically meaningful results. This architecture enables easy multiplexing without exponential design complexity.
New targets can be added or modified computationally, without starting assay design from scratch, while continuing to use existing lab workflows. As a result, teams can adapt panels without repeated primer redesign cycles, reduce assay development and validation timelines by up to 50%, minimise late-stage failures caused by primer interactions or dropouts, and scale reliably from pilot studies to large screening or surveillance programs.
By shifting critical design decisions upstream into computation and molecular programming, AlgoBio enables assays that are not only accurate, but modular, reproducible, and built for scale. The goal is not just to make assays work, but to make them work reliably, repeatedly, and across evolving diagnostic needs.
Looking Ahead
Computational assay design is no longer optional—it is becoming foundational as diagnostics grow more complex, more multiplexed, and more widely deployed. In upcoming blogs, we'll explore how these design principles apply across real-world use cases, including rare disease screening, infectious disease surveillance, cancer diagnostics and monitoring, and newborn screening programs.
Each area brings unique challenges, but the need for smart, scalable, and adaptable assay design remains constant.
From Wet Lab to In-Silico: How Computational Assay Design Enables Scalable Diagnostics
Designing a diagnostic test once started in the lab, but today it increasingly starts on a computer. As diagnostics move toward larger screening programs, faster turnaround times, and lower costs, traditional trial-and-error assay development is no longer enough. This is where computational (in-silico) assay design comes in.
In this blog, we'll walk through what computational assay design actually means, how assays are designed today, where current approaches slow down or break at scale, and how in-silico design helps diagnostics scale efficiently.
What Is Computational Assay Design?
At its core, computational assay design means using algorithms, biological data, and simulations to design and evaluate diagnostic assays before they reach the wet lab.
Instead of testing every primer, probe, or target experimentally, designs are screened digitally, performance is predicted using real genomic data, and weak designs are eliminated early. This approach doesn't replace the lab; it reduces unnecessary lab iterations and helps teams arrive at better assays faster.
How Diagnostic Assays Are Traditionally Designed
Identifying Target Genes or Regions
Most diagnostic assays, whether for infectious diseases, inherited conditions, or cancer, follow a similar path: identify target genes or regions, design primers or probes, test them experimentally, redesign if performance is poor, and repeat until the assay works.
Challenges with Traditional Approaches
While this approach works for small studies, it becomes problematic when panels include dozens or hundreds of targets, samples come from genetically diverse populations, or assays need to scale across multiple labs or sites. Each redesign cycle costs time, reagents, and effort.
Where Traditional Assay Design Struggles at Scale
Too Many Targets, Too Little Time
Modern diagnostics often require highly multiplexed panels, high coverage, and minimal cross-reactivity. Manually evaluating every design combination quickly becomes impractical.
Population Bias
An assay that works well in one population may perform poorly in another due to genetic variation, mutations at primer-binding sites, or emerging strains (especially in infectious diseases).
Late Discovery of Design Issues
Problems like poor specificity, dropouts, or unexpected cross-reactivity are often discovered only after wet-lab testing, when changes are expensive.
Difficulty Standardising at Scale
When assays move from development to deployment, minor design differences can impact reproducibility and scaling across labs becomes harder.
How Computational Assay Design Changes the Workflow
Computational design shifts key decisions earlier in the process. In-silico design allows teams to evaluate thousands of candidate designs virtually, test designs against real genomic databases, simulate edge cases before lab validation, and narrow down to the most robust candidates. This results in fewer wet-lab iterations, better-performing assays, and faster time to deployment.
What This Looks Like in Practice
Target Selection Using Curated Genomic Data
Primer/Probe Design with Specificity Checks
In-silico Validation Against Known Variants
Cross-reactivity and Coverage Assessment
Design Optimisation Before Lab Testing
By the time the assay reaches the bench, it is already pre-filtered for performance.
Why This Matters for Scalable Diagnostics
As diagnostics move toward population-scale screening, surveillance programs, and rapid outbreak response, the cost of inefficient design multiplies. Computational assay design helps ensure that assays are robust across populations, faster to develop, easier to standardise, and more cost-effective at scale. This is especially critical for programs where delays or failures directly impact public health outcomes.
Where AlgoBio Fits In
Sequence Transduction for Scalable Assay Design
AlgoBio addresses this challenge through its proprietary Sequence Transduction platform, a molecular computing based approach that rethinks how nucleic acid assays are designed and scaled. Instead of tying detection directly to target-specific primers, Sequence Transduction converts diverse DNA or RNA targets into programmable proxy sequences that can be quantified using standard qPCR or digital PCR workflows.
Universal Readout Architectures
This decoupling of target recognition from signal readout allows teams to reuse the same PCR chemistry even as targets change, combining programmable sequence transducers, universal readout architectures compatible with existing qPCR and dPCR infrastructure, and molecular logic and multiplexing strategies that enable multiple targets to be processed within a single tube.
Algorithmic Decoding via Tapestry
The platform uses algorithmic decoding via the Tapestry platform, translating proxy signals back into biologically meaningful results. This architecture enables easy multiplexing without exponential design complexity.
New targets can be added or modified computationally, without starting assay design from scratch, while continuing to use existing lab workflows. As a result, teams can adapt panels without repeated primer redesign cycles, reduce assay development and validation timelines by up to 50%, minimise late-stage failures caused by primer interactions or dropouts, and scale reliably from pilot studies to large screening or surveillance programs.
By shifting critical design decisions upstream into computation and molecular programming, AlgoBio enables assays that are not only accurate, but modular, reproducible, and built for scale. The goal is not just to make assays work, but to make them work reliably, repeatedly, and across evolving diagnostic needs.
Looking Ahead
Computational assay design is no longer optional—it is becoming foundational as diagnostics grow more complex, more multiplexed, and more widely deployed. In upcoming blogs, we'll explore how these design principles apply across real-world use cases, including rare disease screening, infectious disease surveillance, cancer diagnostics and monitoring, and newborn screening programs.
Each area brings unique challenges, but the need for smart, scalable, and adaptable assay design remains constant.
From Wet Lab to In-Silico: How Computational Assay Design Enables Scalable Diagnostics
Designing a diagnostic test once started in the lab, but today it increasingly starts on a computer. As diagnostics move toward larger screening programs, faster turnaround times, and lower costs, traditional trial-and-error assay development is no longer enough. This is where computational (in-silico) assay design comes in.
In this blog, we'll walk through what computational assay design actually means, how assays are designed today, where current approaches slow down or break at scale, and how in-silico design helps diagnostics scale efficiently.
What Is Computational Assay Design?
At its core, computational assay design means using algorithms, biological data, and simulations to design and evaluate diagnostic assays before they reach the wet lab.
Instead of testing every primer, probe, or target experimentally, designs are screened digitally, performance is predicted using real genomic data, and weak designs are eliminated early. This approach doesn't replace the lab; it reduces unnecessary lab iterations and helps teams arrive at better assays faster.
How Diagnostic Assays Are Traditionally Designed
Identifying Target Genes or Regions
Most diagnostic assays, whether for infectious diseases, inherited conditions, or cancer, follow a similar path: identify target genes or regions, design primers or probes, test them experimentally, redesign if performance is poor, and repeat until the assay works.
Challenges with Traditional Approaches
While this approach works for small studies, it becomes problematic when panels include dozens or hundreds of targets, samples come from genetically diverse populations, or assays need to scale across multiple labs or sites. Each redesign cycle costs time, reagents, and effort.
Where Traditional Assay Design Struggles at Scale
Too Many Targets, Too Little Time
Modern diagnostics often require highly multiplexed panels, high coverage, and minimal cross-reactivity. Manually evaluating every design combination quickly becomes impractical.
Population Bias
An assay that works well in one population may perform poorly in another due to genetic variation, mutations at primer-binding sites, or emerging strains (especially in infectious diseases).
Late Discovery of Design Issues
Problems like poor specificity, dropouts, or unexpected cross-reactivity are often discovered only after wet-lab testing, when changes are expensive.
Difficulty Standardising at Scale
When assays move from development to deployment, minor design differences can impact reproducibility and scaling across labs becomes harder.
How Computational Assay Design Changes the Workflow
Computational design shifts key decisions earlier in the process. In-silico design allows teams to evaluate thousands of candidate designs virtually, test designs against real genomic databases, simulate edge cases before lab validation, and narrow down to the most robust candidates. This results in fewer wet-lab iterations, better-performing assays, and faster time to deployment.
What This Looks Like in Practice
Target Selection Using Curated Genomic Data
Primer/Probe Design with Specificity Checks
In-silico Validation Against Known Variants
Cross-reactivity and Coverage Assessment
Design Optimisation Before Lab Testing
By the time the assay reaches the bench, it is already pre-filtered for performance.
Why This Matters for Scalable Diagnostics
As diagnostics move toward population-scale screening, surveillance programs, and rapid outbreak response, the cost of inefficient design multiplies. Computational assay design helps ensure that assays are robust across populations, faster to develop, easier to standardise, and more cost-effective at scale. This is especially critical for programs where delays or failures directly impact public health outcomes.
Where AlgoBio Fits In
Sequence Transduction for Scalable Assay Design
AlgoBio addresses this challenge through its proprietary Sequence Transduction platform, a molecular computing based approach that rethinks how nucleic acid assays are designed and scaled. Instead of tying detection directly to target-specific primers, Sequence Transduction converts diverse DNA or RNA targets into programmable proxy sequences that can be quantified using standard qPCR or digital PCR workflows.
Universal Readout Architectures
This decoupling of target recognition from signal readout allows teams to reuse the same PCR chemistry even as targets change, combining programmable sequence transducers, universal readout architectures compatible with existing qPCR and dPCR infrastructure, and molecular logic and multiplexing strategies that enable multiple targets to be processed within a single tube.
Algorithmic Decoding via Tapestry
The platform uses algorithmic decoding via the Tapestry platform, translating proxy signals back into biologically meaningful results. This architecture enables easy multiplexing without exponential design complexity.
New targets can be added or modified computationally, without starting assay design from scratch, while continuing to use existing lab workflows. As a result, teams can adapt panels without repeated primer redesign cycles, reduce assay development and validation timelines by up to 50%, minimise late-stage failures caused by primer interactions or dropouts, and scale reliably from pilot studies to large screening or surveillance programs.
By shifting critical design decisions upstream into computation and molecular programming, AlgoBio enables assays that are not only accurate, but modular, reproducible, and built for scale. The goal is not just to make assays work, but to make them work reliably, repeatedly, and across evolving diagnostic needs.
Looking Ahead
Computational assay design is no longer optional—it is becoming foundational as diagnostics grow more complex, more multiplexed, and more widely deployed. In upcoming blogs, we'll explore how these design principles apply across real-world use cases, including rare disease screening, infectious disease surveillance, cancer diagnostics and monitoring, and newborn screening programs.
Each area brings unique challenges, but the need for smart, scalable, and adaptable assay design remains constant.